ArticleScientific reports2026
Folic acid-loaded amino-functionalized MCM-41 as a drug delivery system for cervical cancer modulating apoptotic and survival signals.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains one of the most prevalent gynecological malignancies worldwide, with high mortality rates particularly in developing countries, necessitating the development of effective and targeted therapeutic strategies. In this study, a folic acid (FA)-loaded amino-functionalized MCM-41 mesoporous silica nanocarrier was developed as a controlled delivery platform for cervical cancer applications. Pure MCM-41 was synthesized via a precipitation method and subsequently functionalized with aminopropyl groups through post-synthesis grafting, followed by FA-loading. Structural, textural and morphological analyses confirmed successful functionalization while maintaining the ordered mesoporous framework. In vitro drug release studies demonstrated pH-responsive behavior, with enhanced folic acid release under physiological conditions (pH 7.4) compared to acidic conditions (pH 1.5), supporting its suitability for controlled delivery applications. Cytotoxicity evaluation using HeLa cervical cancer cells and WI38 normal fibroblasts revealed selective anticancer activity of FA-functionalized systems with minimal toxicity toward normal cells. Among all formulations, the DMSO-based FA-loaded MCM-41 exhibited the highest cytotoxic and apoptotic effects, comparable to Doxorubicin. Mechanistic studies indicated that treatment induced oxidative stress through increased nitric oxide and malondialdehyde levels, accompanied by depletion of antioxidant enzymes (SOD and GSH). Additionally, apoptosis induction was confirmed by an increased Bax/Bcl-2 ratio and activation of the intrinsic mitochondrial pathway, along with suppression of PI3K/AKT survival signaling, along with downregulation of p-AKT. In conclusion, the developed FA-loaded amino-functionalized MCM-41 nanocarrier demonstrates efficient tumor targeting, controlled drug release, and potent apoptosis-mediated anticancer activity, highlighting its potential as a promising platform for cervical cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.